Surat-based Anupam Rasayan completes ₹1,750-cr acquisition of 48.2% in Bliss GVS Pharma
This marks Anupam Rasayan’s third strategic inorganic transaction, as the Surat-based specialty chemicals maker expands into finished pharmaceutical formulations
On Thursday, Anupam Rasayan India Ltd announced the purchase of 22,50,000 shares of Bliss GVS Pharma Ltd through an on-market transaction. The shares were bought at ₹723.2883 per share, representing approximately 2.12 percent of Bliss GVS Pharma's paid-up equity share capital. This acquisition, alongside previous transactions, brings Anupam Rasayan and its associate Mates Visa Consultancy Private Limited's total shareholding to an impressive 50.07 percent of Bliss GVS Pharma.
This move has secured the company control over Bliss GVS Pharma, making them the new promoters as of September 28, 2026. The board of directors of Bliss GVS Pharma has confirmed this change of control and new promoter status. The acquisition is strategic, aimed at strengthening Anupam Rasayan's position in the pharmaceutical value chain, from key medicine suppliers to finished dosage formulations.
This move is expected to enhance forward integration, unlock synergies through innovation and operational efficiencies, and support long-term growth and value creation. Bliss GVS Pharma, a public listed company founded on December 11, 1984, specializes in manufacturing pharmaceutical products like suppositories, pessaries, tablets, capsules, and other specialty pharmaceuticals.
The company's reported turnover for the fiscal years 2023-24, 2024-25, and 2025-26 was ₹1,000.64 crore, ₹846.22 crore, and ₹798.98 crore respectively.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Anupam Rasayan Acquires 22.5 Lakh Shares Of Bliss GVS Pharma For ₹162.74 Crore freepressjournal.in
